Bionano announces significant upgrades to its bionano solve pipeline and its via™ software for ogm data analysis in constitutional genetic disease research

San diego, dec. 28, 2023 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo), today announced significant upgrades to its pipeline for analysis of optical genome mapping (ogm) data in its via™ software for applications in constitutional genetic disease. the latest analysis pipeline, bionano solve 3.8.1, enhances the sensitivity and specificity for structural variation (sv) detection from ogm data, which, when combined with copy number variant (cnv) analysis capabilities introduced in july 2023, further advance ogm's leadership in variant detection. together with the enhanced performance for sv and cnv calling, via software now enables the most comprehensive visualization, interpretation and reporting of svs and cnvs from ogm data in constitutional genetic disease research.
BNGO Ratings Summary
BNGO Quant Ranking